Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5701569 | Journal of Thoracic Oncology | 2017 | 12 Pages |
Abstract
Loss of p16 expression and homozygous deletion of CDKN2A are promising prognostic biomarkers in thymic carcinoma. On the basis of our findings, a subset of thymic carcinomas have the potential to respond to CDK4/6 inhibitors; however, further functional studies are needed.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Scott W. MD, PhD, Marie Christine MD, Eunhee S. MD, Sara M. Kloft-Nelson, Sarah M. MS, Grant M. Spears, Patricia T. DO, William R. MD, Anja C. MD,